



REAL-WORLD REGISTRY  
INITIAL 30-DAY RESULTS  
IN 300 PATIENTS

“

We see very **short learning curves** and the ability to adopt the therapy **safely and effectively**. We see a **great safety profile** and confirm the previous effectiveness results of the TRILUMINATE trial ... It's confirmed looking at much more centers and **reflecting real-world practice**.”

**Prof. Dr. Philipp Lurz**  
bRIGHT Principal Investigator



Scan to learn more about  
TriClip™ TEER



**TriClip™**  
Transcatheter  
Edge-to-Edge Repair



## THE FUTURE OF TRICLIP™ TEER IS bRIGHT<sup>1</sup>

### Objective


Evaluating the safety and effectiveness of TriClip™ TEER in patients with severe TR in a real-world, post-market setting.

### Study Design

Prospective, single-arm, multicenter registry (minimum 500 subjects at approximately 30 sites in Europe).



*Studied in an elderly, fragile, high-surgical risk, real-world patient population*




Information contained herein for DISTRIBUTION outside of the U.S. ONLY. Always check the regulatory status for the device in your region.


# PROVEN IN THE LARGEST BODY OF REAL-WORLD EVIDENCE TO DATE<sup>1,2</sup>

## TriClip™ Therapy Continues to Demonstrate:

### High Procedural Success



### Short Device Time



### High Safety Profile at 30 Days



99.7% survival  
0.3% non-elective CV surgery, TVRS device-related AE  
0% embolization

High rates of success across diverse patient anatomies



2.5–7.6 cm range of annular diameters





2.6–20.8 mm measured gap sizes



TV morphologies with 2–5 leaflets

## Life-changing Outcomes at 30 Days



18 POINTS

significant improvement in KCCQ-OS health-related quality of life

KCCQ-OS = Kansas City Cardiomyopathy Questionnaire Overall Summary  
MAE = major adverse event  
NYHA = New York Heart Association  
TEER = transcatheter edge-to-edge repair  
TR = tricuspid regurgitation

1. Lurz P, Lapp H, Schueler R, et al. Real-world Outcomes for Tricuspid Edge-to-Edge Repair: Initial 30-Day Results from the TriClip™ bRIGHT Study. Presented at: EuroPCR; May 17-18, 2022; Paris, France.  
2. ClinicalTrials.gov. Find a Study. Accessed November 12, 2021. <https://clinicaltrials.gov/ct2/results?cond=tricuspid+regurgitation&term=transcatheter&cntry=&state=&city=&dist=>

The testimonial does not provide any indication, guide, warranty or guarantee as to the response patients may have to the treatment or effectiveness of the product or therapy in discussion. Opinions about the treatment discussed can and do vary and are specific to the individual's experience and might not be representative of others.

CAUTION: This product is intended for use by or under the direction of a physician. Prior to use, reference the Instructions for Use, inside the product carton (when available) or at [eifu.abbottvascular.com](http://eifu.abbottvascular.com) or at [medical.abbott/manuals](http://medical.abbott/manuals) for more detailed information on Indications, Contraindications, Warnings, Precautions and Adverse Events.

Information contained herein for **DISTRIBUTION outside of the U.S. ONLY**. Always check the regulatory status for the device in your region.

**Abbott**  
3200 Lakeside Dr., Santa Clara, CA. 95054 USA

™ Indicates a trademark of the Abbott group of companies.

‡ Indicates a third party trademark, which is property of its respective owner.

[www.structuralheart.abbott](http://www.structuralheart.abbott)

© 2022 Abbott. All Rights Reserved. | MAT-2115505 v2.0 | Item approved for OUS use only.

